STAT@ASCO: Pathways to Progress

About

The annual meeting of the American Society of Clinical Oncology is the biggest showplace for new data on how to treat cancer. Join the FDA’s top cancer drug regulator along with a stellar lineup of researchers, regulators, and industry executives, and STAT’s reporters to talk about the biggest trends in cancer care and research. It will be an evening of spirited discussion about one of medicine’s scariest foes.

Sold out

This event is sold out! Sign up for STAT’s ASCO Recap, Live! where STAT reporters will share convention hall insights, predictions for the months ahead, and answer audience questions.

Agenda

6:00-6:40 p.m. CT – Arrival & Networking Reception

Drinks and light bites will be served.

6:40-6:45 p.m. CT – Welcome from STAT

Matthew Herper, senior writer, medicine; editorial director of events, STAT

6:45-6:50 p.m. CT – How Do We Scale Precision Medicine? Sponsor Session

Advancements in oncology have ushered in a new era of highly targeted, highly effective therapies, offering hope for patients. However, with therapies becoming more precise, there’s a concern about reaching fewer patients. With rising cancer rates worldwide, the question arises: Can we effectively scale precision medicine to meet the needs of all patients? A discussion on a new “blueprint for access,” emphasizing collaboration across the therapy-to-patient journey, aims to enable access to transformative therapies for everyone.
Doug Fulling, president, Precision AQ

6:50 p.m.-7:25 p.m. CT – Inside the Drug Industry’s War on Cancer

Hear from top officials at some of the largest companies working in cancer today. Which areas are hot, and which are not? Where can we expect innovation, and what are the biggest challenges ahead? These companies make some of the biggest cancer drugs in the world, and their leaders will provide insights you can’t get anywhere else.
Chris Boshoff, M.D., Ph.D., chief oncology officer and executive vice president, Pfizer
Susan Galbraith, Ph.D., executive vice-president, oncology R&D, AstraZeneca
Levi Garraway, M.D., Ph.D., executive vice president, head of global product development and chief medical officer, Genentech
Ken Keller, global head of oncology business, Daiichi Sankyo; president and CEO, Daiichi Sankyo, Inc.
Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

7:25-7:35 p.m. CT – How Advancements in Biomarker Testing Pave the Way for Better Lung Cancer Treatment Sponsor Session

For decades, lung cancer seemed unbeatable. But the identification of gene mutations as oncogenic drivers in patients with non-small cell lung cancer (NSCLC) was the catalyst for a new era of targeted treatment options and advancements in comprehensive diagnostic testing. Advances in biomarker testing have helped fueled the next generation of targeted treatment options. Come hear how Foundation Medicine has been at the forefront of precision medicine – and how the company channels knowledge and expertise into creating high-quality diagnostic tests that deliver the highest level of confidence for NSCLC patients.

Mia Levy, M.D., Ph.D., chief medical officer, Foundation Medicine
Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

7:35-8:00 p.m. CT – Rick Pazdur Speaks

One of the most influential regulators in medicine takes the stage to give candid assessments of the status of cancer research, drawing on his unique, panoramic view of drugs in development.
Richard Pazdur, M.D., director, Oncology Center of Excellence; acting director, Office of Oncologic Diseases – CDE Offices and Divisions, U.S. Food and Drug Administration
Adam Feuerstein, senior writer, biotech, STAT (moderator)

8:00-8:25 p.m. CT – Rick Interviews STAT

Pazdur will ask tough questions of STAT reporters, putting them in the hot seat.
Adam Feuerstein, senior writer, biotech, STAT
Matthew Herper, senior writer, medicine; editorial director of events, STAT
Richard Pazdur, M.D., director, Oncology Center of Excellence; acting director, Office of Oncologic Diseases – CDE Offices and Divisions, U.S. Food and Drug Administration (moderator)

8:25-8:30 p.m. CT – Closing from STAT

8:30-9:00 p.m. CT – Networking Reception Continues

Drinks and light bites will be served.